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Regional changes in the intrarenal insulin-like growth factor-I axis in
diabetes. Since insulin-like growth factor-I (IGF-I) has been shown to
promote renal growth and as kidney IGF-I content increases during the
early days after the onset of diabetes, it is likely that this growth factor
contributes to initial diabetic renal hypertrophy. However, it is unclear
whether IGF-I contributes to the continued renal growth that occurs in
diabetes. Since IGF-I action is mediated through its receptor and as its
bioavailability is regulated by IGF binding proteins (IGFBP), we postu-
lated that changes in IGF-I receptor binding or IGFBP production may
favor a role for IGF-I in diabetic renal growth when kidney IGF-I levels
have returned to normal. To test this thesis, we studied kidneys of rats
after seven days of streptozotocin diabetes. In diabetic cortex and medulla,
growth hormone receptor mRNA levels and IGF-I and IGF-I receptor
mRNA and protein product levels were unchanged. In cortex IGFBP-1
mRNA levels were increased while IGFBP-2 and -4 mRNA levels
decreased. In medulla the only change was a fall in IGFBP-1 mRNA
levels. Using Western ligand blot we observed an increase in a 32 kDa
plasma membrane-associated TGFBP. Insulin therapy reversed all changes
except the elevated cortical IGFBP-l mRNA levels, indicating the pres-
ence of regional heterogeneity in the IGFBP response to diabetes in the
kidney. However, the lack of change in IGF-I, IGF-I receptor and growth
hormone receptor gene expression and protein products after one week of
diabetes argues against a role for IGF-I in sustaining diabetic renal growth
beyond the initial growth phase.
Diabetes mellitus is now the leading cause of end-stage renal
failure in the USA. A feature of early diabetes is renal enlarge-
ment and hyperfunction [1]. In many instances, this appears to be
the forerunner of structural damage leading to loss of renal
function. In rats, diabetic nephromegaly is almost invariably
followed by pathologic changes. This lead to the concept that
identification of factors that drive the kidney to enlarge in
diabetes will contribute significantly to our understanding of the
pathogcnesis of diabetic nephropathy. Insulin-like growth factor-I
(IGF-I) is among the many factors that could potentially play a
role in diabetic kidney enlargement and hyperfunction [2—5]. This
peptide growth factor promotes renal growth [4, 6] and increases
renal blood flow and glomerular filtration [7]. It is present in the
circulation largely derived from the liver, hut is also produced
within kidney and other tissues mainly under the influence of
growth hormone (GH). In early experimental diabetes in the rat,
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kidney IGF-I content increases transiently [8, 9] though the
mechanism for this increase is unknown. When this increase is
blocked by treatment with a somatostatin analogue, then renal
hypertrophy does not occur [10]. For these reasons it has been
suggested that IGF-I may play an important role in the develop-
ment of diabetic renal hypertrophy and, perhaps, diabetic kidney
disease.
Other components of the IGF-I axis may also play a role in
mediating diabetic renal hypertrophy. These include the growth
hormone (GH) and IGF-I receptors and the insulin-like growth
factor binding proteins (IGFBP). These binding proteins have a
high affinity for IGF-I and, by sequestering the growth factor,
IGFBPs affect hormone delivery to cells and thereby modulate its
bioactivity [11, 12]. Six distinct IGFBP have been identified and all
are expressed in the kidney, although IGFBP-6 is present in very
low abundance [Ii, 13]. These proteins are produced in tissues
throughout the body and several, especially IGFBP-3, are present
in high concentration in the circulation.
In diabetes the production of IGFBPs in a variety of tissues
including kidney is altered, with some IGFBPs increasing, some
decreasing and some remaining unchanged [3, 12]. Thus, it is
possible that local alterations in the intrarenal content of IGF-I
and its modulating IGFBPs and perhaps the IGF-I receptor could
result in enhanced local IGF-I action, which could then contribute
to the development of renal hypertrophy and ultimately to renal
pathology. As a first step in pursuing this hypothesis, we studied
rats with early streptozotocin (STZ) induced diabetes and have
characterized the regional changes in expression of genes that
encode proteins comprising the intrarenal IGF-I axis [4]. Included
in this study are the GH and IGF-I receptors, IGF-l and IGFBP-i
through -5.
Methods
Male Sprague-Dawley rats weighing —200 g and allowed free
access to food and water were studied. Rats were divided into
three groups: diabetics, insulin treated diabetics and non-diabetic
controls. Diabetes was induced by i.v. injection of 55 mg/kg of
streptozotocin (Sigma Chemicals, St. Louis, MO, USA). Control
rats received vehicle alone. Two days later blood glucose levels
were checked and only rats with glucose levels above 250 mg/dl
were included in the study. One group of diabetic animals was
treated with insulin beginning two days after the injection of STZ.
Long-acting, heat-treated ultralente insulin (Novo, Denmark) was
given at an initial dose of 10 IU s.c. followed by 2 to 6 IU daily
according to the blood glucose level measured by a glucometer
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(Companion 2; Medisense, Waltham, MA, USA). Serum glucose
on day 2 and day 7 were measured with a Glucose Analyzer 2
(Beckman, Fullerton, CA, USA). Seven days after STZ or vehicle
injections rats were anacsthetized, the right kidneys were re-
moved, weighed, separated into cortex and medulla and frozen in
liquid nitrogen and stored at —80°C until processing. Left kidneys
were perfused in Situ with phosphate buffered saline (37°C) until
free of blood, and collected and stored as above.
Preparation of crude kidney membranes
Crude plasma membranes were isolated separately from cortex
and medulla as previously described [14]. Briefly, kidneys were
homogenized in 8% buffered sucrose followed by differential
centrifugation and collection of a 47,000 g pellet. The pellet was
resuspended in calcium-free Krebs-Ringer Hepes buffer (KRH,
pH 7.4) and stored at —80°C. Membrane protein content was
measured with the Bio-Rad method (Bio-Rad Laboratories, Rich-
mond, CA, USA).
Kidney membrane IGF-I receptor binding assay
IGF-I binding was measured exactly as previously described
using recombinant human IGF-l (a gift from Genentech Inc.,
South San Francisco, CA, USA), radiolabcled with '251-Na [141.
In brief, 100 j.tg of crude plasma membrane protein were incu-
bated with 10 ' M '251-IGF-l in calcium-free KRH containing
0.5% BSA, 2 mM bacitracin and 5 mrvi N-ethylmaleimide at 4°C
overnight. Membrane-bound and free 1251-IGF-l were separated
by centrifugation, the pellet was washed and the radioactivity
counted. Non-specific 1251-IGF-I binding was determined from
incubation with 10_6 M of unlabeled IGF-I.
Western ligand blot
Cortical and medullary plasma membranes prepared from
saline perfused kidneys were used. Membrane protein, 100 jtg,
was electrophoresed in 12% polyacrylamide gel. Separated pro-
teins were electroblotted onto nitrocellulose filters (Biorad Semi-
Dry Transfer Cell) and then incubated with a solution containing
one million cpm of 1251-IGF-l and 1251-IGF-II overnight at 4°C
and visualized by autoradiography [15]. Measurement was by
densitometty, though it should be recognized that this is not truly
quantitative because of variations in the transfer of proteins to the
nitrocellulose.
Radioimmunoassay of serum and kidney IGF-I
As before [14], IGF-l was measured by radioimmunoassay in
acid-ethanol extracts prepared from serum and saline perfused
whole kidneys with a commercial assay kit (Nichols Institute, San
Juan Capistrano, CA, USA). Recovery of IGF-1 added to homog-
enate of kidneys from control, untreated diabetics and treated
diabetic rats averaged 99 2.8%, 98 4.8% and 88 1.5%,
respectively. Recovery from serum averaged 91 2.6%, 88
4.1% and 95 2.6%, respectively.
RNA extraction
Total RNA was isolated separately from the cortex and medulla
by an acid guanidinium thiocyanate-phenol chloroform single step
method [161.
Preparation of radiolabeled probes
For the solution hybridization/RNase protection assay, radiola-
beled antisense IGF-I, IGF-1 and GH receptor and 18S ribo-
probes were prepared with 32P-CTP [14]. The IGF-l riboprobe, a
376 bp Sau3A-EcoRl fragment, was designed to detect both the
Ea and Eb IGF-I mRNAs [17]. The IGF-I receptor riboprobe
contained 280 bases complementary to the IGF-I receptor
mRNA. The GH receptor riboprobe contained 137 bases (posi-
tion 811 to 948) complementary to the rat GH receptor mRNA
(Dr. L.S. Mathews, University of Michigan) [181. The 18S ribo-
probe contains 80 bases complementary to a highly conserved
region of the human RNA [19]. For Northern blot analysis the
cDNA probes were labeled with 50 jsCi 32P-dCTP by a random
primer method (DNA labeling kit 70200; United States Biochem-
ical Corporation, Cleveland, OH, USA). Purification of radiola-
beled cDNA probes were achieved through a G-50 Sephadex
column.
The cDNA probes for the five IGFBPs studied were prepared
from rat cDNAs (Dr. S. Shimasaki, Whittier Institute, La Jolla,
CA, USA). Probes were prepared by synthesizing the correspond-
ing cDNA by PCR using the cloned cDNA as a template [11]. The
IGFBP-1 probe consisted of 407 bp corresponding to the coding
region spanning nucleotide position 486 to 892 in the rat IGFBP-1
cDNA sequence. The IGFBP-2 probe was comprised of 342 bp
spanning nucleotide position 670 to 1011. The IGFBP-3 probe
comprised 636 bp spanning nucleotide positions 196 to 831. The
IGFBP-4 probe consisted of 354 bp spanning nucleotide position
487 to 840. The IGFBP-5 probe comprised 259 bp spanning
nucleotide position 856 to 1114.
Northern blot analysis
Total RNA was size-separated by formaldehyde agarose gel
electrophoresis [141. Briefly, RNA was denatured with 0.55 M
formaldehyde. Samples containing 20 jsg RNA were loaded and
electrophoresed on a denaturing agarose gel containing 0.55 M
formaldehyde and stained with ethidium bromide. RNA was
transferred to nitrocellulose filters, fixed to the filters by UV
cross-link (UV 1800 Stratalinker; Stratgene, La Jolla, CA, USA)
and photographed under tJV light. Filters were then prehybrid-
ized in a solution containing 50% formamide, 1.5 X SSPE, 2.5 ><
Denharts solution, 50 pg salmon sperm DNA, 0.2% SDS at 42°C
for four hours. The mRNA levels of IGFBP-1, -2, -3, -4, and -5
were detected by hybridizing 32P-radiolabeled eDNA probes to
the mRNA at 42°C overnight. Washed filters were then exposed
to Kodak XAR films (Kodak, Rochester, NY, USA) for two to
seven days. The abundance of each IGFBP mRNA was measured
by scanning densitometry (Ultrascan XL; Pharmacia LKB Bio-
technology, Inc., Alameda, CA, USA) and adjusted for the levels
of the 18S rRNA readings obtained from photographic negatives
of the nitrocellulose filters [14].
Solution hybridizationiRNAse protection assay
These assays were performed as previously described [14J. in
brief, labeled antisense IGF-i, IGF-l and GH receptor and 18S
RNAs were synthesized using 32P-Iabeled CTP. Total RNA, 20
jig, was hybridized with 32P-CTP labeled antisense IGF-I or IGF-I
receptor RNA probes overnight at 42°C in 75% formamide/400
mM NaCI. After hybridization, the mixture was added to RNAse
digestion buffer containing RNAse A (25 pg/mI) and RNAse T1
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Table 1. Body weight, serum glucose and kidney weight
Group N
Body
Day 0
wt g
—-—--
Day 7
.
Kidney wt g
Day 7
.
Kidney wt/body wt %
Day 7
Glucose mg/dI
Day 2 Day 7
Control 5 199 2 256 3 1.23 0.05 0.48 0.02 133 04 148 02
Diabetic 5 197 1 235 l' 1.45 0.04k' 0.62 0.04t 389 25 479 27b
°Treated diabetic 5 199 2 248 2 1.28 0.06 0.50 0.03 419 26 108 14
Data are mean SEM.
"Insulin treatment was started 48 hours after administration of streptozotocin
h P < 0.05 vs. control
(50 U/ml) and incubated at 30°C for one hour. After that,
proteinase K (200 tgIml) was added and incubated at 37°C for 30
minutes. Protected hybrids were precipitated by ethanol and
separated on a 5% polyacrylamide/8 M urea denaturing gel.
Autoradiographs were obtained and the protected bands were
measured by densitometry. Only the Ea IGF-I mRNA transcripts
were increased since it accounted for > 95% of the IGF-I mRNA
signal in the kidney.
Data analysis
Autoradiographic densitometry readings of the mRNAs of
interest were adjusted for the corresponding 18S rRNA reading.
Results are expressed as the mean SEM. The data were analyzed
with a one-way analysis of variance and if the F ratio was
significant, Fischer's paired least significance difference test was
used to detect differences between the diabetic and control
groups. A P value < 0.05 was taken as significant. The average of
the controls was assigned a value of 100 and all results were
expressed in relation to this value.
Results
Serum glucose levels and body and kidney weight
The results from the three groups of animals studied are listed
in Table 1. The serum glucose was higher (479 27 mg/dl) and
the body wt was lower in the diabetics at the end of the seven day
study. In contrast to body wt, diabetic kidney wet wt was 18%
greater than that of non-diabetic controls (1.45 0.04 g vs. 1.23
0.05 g respectively, P < 0.05). Insulin treatment for five days prior
to sacrifice prevented the hyperglycemia, relative body wt loss and
renal hypertrophy.
mRNA levels
Kidney cortex. The relative IGFBP mRNA levels are depicted in
Figure 1. In the untreated diabetic kidney cortex, the IGFBP-1
mRNA levels were increased by 60% over the control values (P <
0.05). In contrast, IGFBP-2 and -4 mRNA levels were significantly
decreased by 56% and 48%, respectively. Binding protein-3 and -5
mRNA levels tended on average to be lower in diabetics com-
pared to controls, but did not reach statistical significance.
Following treatment with insulin the mRNA levels of IGFBP-2
through IGFUP-5 reached values that did not differ from the
controls. However, IGFBP-1 mRNA levels remained elevated.
Cortical IGF-l and IGF-I receptor mRNA levels did not differ
significantly between the study groups (Fig. 2 and Table 2).
Similarly, the GI-l receptor mRNA levels, while on average lower
in the diabetics, did not differ significantly from controls (Table 2).
Kidney medulla. As depicted in Figure 3, the relative IGFBP-1
mRNA levels were decreased by 51% in untreated diabetics
compared to controls (P < 0.05). Following insulin treatment the
IGFBP-1 mRNA returned to control levels. There were no
significant differences in the IGFBP-2 to -5 mRNA levels among
the three groups. While the relative IGF-I mRNA levels in
medulla were modestly lower in the diabetic kidneys, they did not
differ significantly from the controls (78 10 vs. 100 10
arbitrary units, respectively). Similarly, the IGF-I receptor and
GH receptor mRNA levels in the medulla were not significantly
altered by the diabetic state (Table 2).
It is noteworthy that when the relative abundance of IGFBP
mRNA levels in cortex and medulla were compared marked
heterogeneity was evident. Most striking was a sixfold greater
abundance of IGFBP-5 mRNA in medulla (Table 3).
Liver. In liver from untreated diabetic rats, the IGFBP-1 and -2
mRNA levels were increased by 2.9- and 2.7-fold, respectively,
compared to controls (P < 0.01; Fig. 4). Binding protein-3 and -4
mRNA levels were decreased by 36% (P < 0.01). All these
changes except for the IGFBP-3 mRNA levels were corrected
with insulin treatment. Interestingly, insulin therapy does not
correct hepatic IGFBP-3 levels in BB/W rats with spontaneous
diabetes [20]. Binding protein-S mRNA levels were not detected
in liver by Northern blot analysis. The IGF-I mRNA and GH
receptor mRNA levels did not differ significantly between the
three groups (Table 2).
Protein levels
IGF-I receptor binding. The specific binding of radiolabeled
12511GF1 to the IGF-I receptors in crude cortical plasma mem-
brane was similar in all three groups. Specific binding per/100 jtg
protein averaged 6.0 0.4% in controls, 5.6 0.7% in the
untreated diabetics and 5.6 0.2% in insulin treated diabetics.
Similar to cortex, specific binding of 125l-IGF-1 to receptors in
crude medullary plasma membranes was not different between the
groups and averaged 8.9 0.1% in controls, 8.8 0.5% in the
untreated diabetics and 8.9 0.7% in insulin treated diabetics.
Membrane associated JGF binding proteins. Western ligand blot
analysis of cortical and medullary plasma membranes revealed
two IGFBPs of molecular weight 24 and —32 kDa each; the 24
kDa signal was stronger in the cortex (Fig.A) while the 32 kDa
signal was stronger in medulla (Fig. SB). The protein of molecular
wt 24 kDa protein is consistent with the size of IGFBP-4, while the
32 kDa protein with IGFBP-i and IGFBP-2. Densitometric
analysis of the ligand blots of cortical plasma membranes showed
that the 24 and 32 kDa signals were not significantly altered by
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Fig. 1. Kidney cortex IGFBP gene expression. Relative IGFBP-1, -2, -3, -4, and -5 mRNA levels in kidney cortex from control (, c) diabetic (, d) and
insulin treated diabetic (U, td) rats. Diabetes was induced with streptozotocin, 55 mg/kg i.p. and the rats studied seven days later. mRNA levels were
detected by Northern blot analysis and corrected for the amount of 18S RNA transferred. Corrected values are expressed relative to the average value
of the control group, which is assigned a value of 100. Representative autoradiograms are shown. Results are mean 5EM, 5 rats/group; * < 0.05;
< 0.01.
Control Diabetic Treated
—IGF—lr
—IGF—l
—1 8S
Fig. 2. Insulin-like growth factor-I, IGF-I receptor (IGF-Ir) and growth hormone receptor (GI-Ir) mRNA levels in cortex from control, diabetic and
insulin-treated diabetic rats. IGF-I and IGF-Ir mRNA levels were determined in the same assay. Messenger RNA levels were detected by a solution
hybridization ribonuclease protection assay and in each assay the 18S RNA was determined.
diabetes. Analysis of medullary membranes showed a significant to five membrane preparations per group. The values in the
(60%) increase in the 32 kDa signal in diabetes (P < 0.01) but no control, diabetic and insulin treated groups were 652 66, 1053
change in the 24 kDa signal. Insulin treatment reduced the 101 and 219 76 arbitrary units, respectively (P < 0.01).
medullary 32 kDa signal by 66% compared to control values (P < IGF-I concentration. Serum IGF-I concentration measured on
0.01). Densitometry readings were obtained separately with four day 7 did not differ significantly between the control, diabetic and
I I H HH __ I I
a
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Table 2. Relative IGF-I, IGF-I receptor (IGF-Ir) and GH receptor (GHr) mRNA levels in kidney and liver
IGF-I IGF-Ir
c
GHr
d tdc d td c d td
Cortex 100± 10 85±5 95±5 100± Il 100±8 135±18 100±6 84±4 112±9
Medulla 100± 14 78±10 96±11 100± 21 88±25 69±8 100±10 91±16 90±11
Liver 100± 4 86±8 97±9 — — — 100±6 104±8 85±8
The mRNA levels are corrected for 185 RNA signal and expressed relative to the average control value (assigned a value of 100). Abbreviations are:
c, control; d, diabetic; td, insulin treatcd diabetic. Data are mean SCM.
IGFBP-1 IGFBP-2 IGFBP-3 IGFBP-4 IGFBP-5
c d c d c d c d c d
Fig. 3. Kidney medulla IGFBP gene expression. Relative IGFBP-1, -2, -3, -4, and -5 mRNA levels measured by Northern blot assays in the medulla of
the kidneys depicted in Figure 1. Results were analyzed in the same manner. Symbols are: (El) control; () diabetic; ( insulin-treated diabetic rats;
'P C 0.05.
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Table 3. Relative IGFBP mRNA levels in cortex and medulla of
kidneys from normal rats
Insulin-like growth factor binding protein
-l -2 -3 -4 -5
Cnrtcx 100 12 100 14 lOt) 15 tOO 11 100 20
Medulla 212 3l 39 4" 24 4" 40 2 628 102h
Northern blots prepared from RNA cxtracted from cortex and medulla
were hybridized with IOFBP eDNA probes. Thc autoradiographic signals
were measured by densitometry and are expressed relative to the avcragc
of the cortical readings, which are taken to equal 100. Data are mean
SCM.
"p < 0.05; 5P C 0.01
insulin treated groups, and averaged 1379 114, 1096 89 and
1197 58 ng/ml, respectively. Similarly, the whole kidney IGF-I
concentration did not differ between the three groups and aver-
aged 5.2 0.66, 5.0 0.38 and 6.0 0.47 ng!mg protein,
respectively.
Discussion
Several studies suggest that IGF-I may be an important medi-
ator of early diabetic renal hypertrophy [31. In rats with diabetes,
kidney IOF-I content increases during the first three days of the
disease and the initial increase precedes the earliest measured
increase in kidney function, RNA and protein content [5, 9].
Furthermore, treatment with octreotride, a somatostatin analog
that suppresses GM secretion, completely inhibits the rise in
kidney IGF-I content and prevents renal hypertrophy and albu-
minuria [10, 21]. Along a similar line of reasoning is the observa-
tion that diabetic OH deficient rats have a smaller increase in
kidney size and [OF-I content than diabetic non-OH deficient rats
[22]. Interestingly, diabetic prepubertal rats do not show the early
increase in kidney IOF-I content seen in mature rats, and diabetic
renal hypertrophy is delayed and somewhat reduced at this age
[23]. Thus, taken together these studies point towards a role for
IGF-I in initiating early diabetic renal hypertrophy.
While there is general agreement that kidney IGF-I content
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Fig. 4. Hepatic IGFBP gene expression. Relative
IGFBP-1, -2, -3, -4, and -5 mRNA levels in the
liver from the same animals studied in Figure 1.
mRNA levels were detected by Northern blots
and analyzed as before. Symbols are: (U)
control; () diabetic; (•) insulin-treated
diabetic rats; cc 0.01.
A Control Treated Diabetic B Control Treated Diabetic/\ /\ /\ /\ /N /\
Fig. 5. Representative Western ligand blot of plasma membrane-associated IGF binding proteins. Membranes were prepared from cortex (A) and medulla
(B) of saline perfused kidneys of control (c), diabetic (d) and insulin-treated diabetic (td) rats. The membranes from 5 rats in each group were pooled
and run in duplicate. Membranes from each rats were also run separately and quantitated by densitometry.
increases transiently in early diabetes [5, 9, 23], controversy exists
as to the effect on JOF-I gene expression. With adult rats there are
reports of a lack of change [9, 24], a fall [25] or even an STZ
dependent increase in kidney IGF-T mRNA levels [26]. It is likely
that these inconsistencies reflect variations in the duration and
severity of diabetes, sex and age of the study animals and the dose
of STZ used to induce diabetes. Several explanations have been
put forward to account for the paradoxical increase in kidney
lOP-I content in the presence of unchanged IGF-I mRNA levels
[6]. These include increased translation of the IOF-I mRNA,
trapping of lOP-I by kidney IGFBPs or receptors, or a slowing of
the cellular breakdown of internalized IGF-I.
In the present report we have sought evidence for the partici-
pation of IOF-I in the ongoing process of renal hypertrophy that
continues for several weeks after the onset of diabetes in the rat
[27]. Studying rats one week after the induction of moderate
diabetes we found regional changes in the TOP-I axis in the
hypertrophying kidney. These changes, which differed between
cortex and medulla, were limited to perturbations in IGFBP gene
expression; the mRNA levels of lOP-I and the lOP-I and OH
receptors were unaltered at this time. Kidney IGF-I protein levels
were also unchanged. Interestingly, in liver the IOFBP gene
expression was also perturbed, but in a different pattern compared
to kidney. As in kidney hepatic IGF-I mRNA and OH receptor
mRNA levels were unaffected by diabetes.
Regarding the IOF-T receptor protein, we found that kidney
plasma membrane IOF-I receptor binding was unaffected after
one week of diabetes. This finding is consistent with Marshall et al
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[5] who also studied kidney IGF-I receptor binding after a week of
diabetes. In contrast, Werner and associates [28] studying 14-day-
old diabetic rats noted a 2.5-fold increase in kidney IGF-I
receptor mRNA levels and a similar increase in receptor binding.
These differences likely reflect the changing response of the
kidney to diabetes over time.
In kidney cortex, where the IGFBP-1 gene is normally ex-
pressed in glomeruli and distal convoluted tubules [13], we found
a significant increase in IGFBP-1 mRNA levels in the diabetic
kidneys which exceeded the non-diabetic values by 60%. In
contrast, cortical IGFBP-2 and IGFBP-4 mRNA levels fell by
56% and 48%, respectively. In the cortex the genes for IGFBP-2
and IGFBP-4 are normally expressed in glomeruli and proximal
tubules, respectively [13]. In renal medulla the only significant
change noted in the diabetic kidney was a 51% fall in the IGFBP-1
mRNA level. This gene is normally detected in the thick ascend-
ing limb of Henle. In liver there was a near threefold increase in
IGFBP-1 and IGFBP-2 mRNA levels and a 35% decrease in
IGFBP-4 mRNA levels. In liver we noted an increase in the
IGFBP-1 and IGFBP-2 mRNA levels and this is consistent with
an earlier report [29]. Insulin treatment corrected the hypergly-
cemia and reversed all the changes in the kidney and liver, except
that IGFBP-1 mRNA levels in kidney cortex remained elevated.
Since insulin treatment normalized JGFBP-1 levels in renal
medulla and in liver, it is likely that the lack of cortical IGFBP-1
response reflects a direct local effect of STZ rather than a
secondary effect of diabetes. Of note, when the relative abundance
of the individual IGFBPs in cortex and medulla were compared,
heterogeneity of abundance was apparent. Most striking was the
IGFBP-5 mRNA level that was sixfold greater in medulla. These
findings are consistent with our in situ hybridization study [13].
The changes in kidney IGFBP expression noted above are
largely consistent with a report by Landau et a! [27] who studied
the diabetic kidney by means of in situ hybridization. In rats
studied seven days after the induction of STZ diabetes, these
authors found a twofold increase in the IGFBP-1 mRNA level in
the cortex while the mRNA levels in the inner stripe of the outer
medulla were reduced markedly. These changes persisted over the
six months of study. There was also a significant reduction in
cortical IGFBP-4 mRNA levels. Finally, there were modest
changes in IGFBP-5 mRNA levels that were decreased in cortex
and increased in outer medulla.
Because of the altered IGFBP gene expression in the kidney the
potential impact on IGF-I action requires consideration. In
general, circulating and tissue IGFBPs act as carriers for IGF-I
with the protein bound IGF-I forming a reservoir from which the
free IGF-l is slowly released. This process reduces the immediate
hioavailability of IGF-l and thus the IGFBPs are largely inhibi-
tory. However, under selected conditions some IGFBPs can
actually enhance the mitogenic activity of IGF-I action on certain
cell types such as fibroblasts and osteoblasts [30, 311. There is little
information on the function of IGFBPs function in kidney, though
the marked anatomical of IGFBP gene expression in the kidney
suggests diversity of function [131. In studies with cultured rabbit
proximal tubule cells we noted that endogenous IGFBPs and
exogenous recombinant human IGFBP-3 inhibited IGF-l induced
mitogenesis [32]. Similarly, recombinant human IGFBP-3 and
IGFBP-1 inhibited mitogenesis in cultured proximal-like oppo-
sum kidney cells [33]. In contrast, there is a preliminary report
that indicates that IGFBP-2 enhances IGF-I stimulated DNA
synthesis in MDCK cells, a cell line derived from the distal
nephron [34]. Accordingly, until the complex interactions between
IGF-I, the binding proteins and the different cell types of the
kidney are unravelled the true significance of the changes in
IGFBP gene expression induced by diabetes will remain obscure.
We did not find any significant changes in cortical plasma
membrane-associated IGFBPs after one week of moderate dia-
betes. However, there was a significant, 60% increase in the 32
kDa IGFBP associated with medullary plasma membrane. This
protein is consistent with the kidney plasma membrane associated
immunoreactive IGFBP-5 identified by Hise et a! [35]. Since our
assay cannot detect IGFBPs in the interstitial or intracellular
compartments, it is conceivable that changes may be present in
these compartments that are below the sensitivity of the assay.
While there are reports of increased IGFBPs in the diabetic
kidney, it is unclear whether these proteins are produced in the
kidney or derived from the systemic circulation [36—38]. For
example, Flyvbjerg et al [38] reported a transient early increase in
the 30 kDa and 38 to 47 kDa IGFBP species in the kidney that
returned to basal levels after four days of diabetes. Since the
serum levels levels were also elevated at that time, these IGFBPs
may have originated from the circulation.
In this study we have noted that there are regional changes in
the expression of IGFBP genes and of a 32 kDa medullary plasma
membrane-associated IGFBP in the kidney after one week of
diabetes. However, it is difficult to conceive how these local
changes can account for the diffuse renal hypertrophy that is
occurring at this time. Thus, taken together with the lack of
change in IGF-I and IGF-I receptor gene and protein expression,
we conclude that it is unlikely that IGF-I contributes to the global
renal hypertrophy that is present at this stage of diabetes.
Whether IGF-I participates at a later stage when the structural
changes of diabetic kidney disease develops remains to be estab-
lished. In this regard Muchaneta-Kubara, Cope and El Nahas [39]
described the biphasic pattern of IGF-I expression in the remnant
kidney following renal ablation, which suggested that IGF-I may
be involved in the early trophic response and again later in the
process of renal scarring.
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